We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.55 | 329,451 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.50 | 0.60 | 0.55 | 0.55 | 0.55 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 2k | -1.27M | -0.0032 | -1.72 | 2.17M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:42:17 | O | 68,666 | 0.578 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/12/2024 | 07:00 | UK RNS | N4 Pharma PLC New Patent Filing |
| 28/11/2024 | 07:00 | UK RNS | N4 Pharma PLC Grant of Options |
| 01/11/2024 | 07:00 | UK RNS | N4 Pharma PLC N4 Pharma CEO Q&A Now LIVE |
| 24/10/2024 | 06:00 | UK RNS | N4 Pharma PLC New Corporate Presentation |
| 24/9/2024 | 14:01 | ALNC |  EARNINGS: Metals One advances Black Schist, N4 generates revenue |
| 24/9/2024 | 06:00 | UK RNS | N4 Pharma PLC Interim Results |
| 17/9/2024 | 07:04 | UK RNS | N4 Pharma PLC SRI Research Update |
| 09/9/2024 | 06:00 | UK RNS | N4 Pharma PLC Director Appointment |
| 23/8/2024 | 07:30 | UK RNS | N4 Pharma PLC Change of Auditor |
| 20/8/2024 | 10:52 | ALNC | IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec |
N4 Pharma (N4P) Share Charts1 Year N4 Pharma Chart |
|
1 Month N4 Pharma Chart |
Intraday N4 Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 06/12/2024 | 15:36 | N4 Pharma | 4,234 |
| 20/5/2021 | 07:25 | N4 Pharma - Making good drugs better. | 4,391 |
| 14/9/2020 | 06:40 | N4P Covid-19 Wealth Warning | 108 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-11 15:42:18 | 0.58 | 68,666 | 396.89 | O |
| 2024-12-11 10:31:02 | 0.60 | 250 | 1.50 | O |
| 2024-12-11 09:52:12 | 0.52 | 88,704 | 456.83 | O |
| 2024-12-11 08:55:57 | 0.58 | 171,581 | 995.00 | O |
| 2024-12-11 08:32:49 | 0.60 | 250 | 1.50 | O |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by N4 Pharma Daily Update N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.55p.N4 Pharma currently has 394,780,000 shares in issue. The market capitalisation of N4 Pharma is £2,171,290. N4 Pharma has a price to earnings ratio (PE ratio) of -1.72. This morning N4P shares opened at 0.55p |
Posted at 23/11/2024 09:37 by pwal Tweet:The @humancellatlas is transforming our understanding of health and disease. With newly uncovered cell types, including those linked to inflammation in #IBD, advanced therapies targeting specific cells such as Nuvec®, will be more in demand: bbc.co.uk/news/artic |
Posted at 12/11/2024 12:27 by pwal The price has moved because of the large spread. Hopefully that will close up and we can see a real rise. |
Posted at 11/11/2024 13:49 by pwal Who thinks N4P can hit 1p before the end of the year? |
Posted at 04/11/2024 17:37 by earwacks Yes it is all very exciting. IBD has come to the forefront now which is possibly their biggest market. The risk is still pretty high, but at least not a one trick pony as they explore other avenues. I think the failure of the Covid vaccine was seen possibly wrongly as a make or break situation and it spiralled as a result. The thing is the cash runway is not huge, so if nothing happens in next six months there will almost certainly be another call for cash. The cynic in me says this is what this current PR is all about to get the price up. The major change this year is The oral IBD drug and of course the competition threat. Should keep Nigel sharply focussed on a deal |
Posted at 04/11/2024 17:27 by pwal So target price range for 2025 is 10 to 30p!Now that's not bad. |
Posted at 25/10/2024 12:28 by fido People should take a look at the PDF.In it the company clearly states that the upside from here is 20-50 times which would value N4P at more than 100 million. |
Posted at 24/10/2024 08:35 by pwal Well I guess now is the time to stock up on N4P. But it will be a slow burner.The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years |
Posted at 10/10/2024 07:08 by pwal Come on N4P! |
Posted at 05/10/2024 06:17 by earwacks No shortage of anguish for shareholders of N4P. It all still looks very plausible if a bit stretched. Certainly they have a product that if proven to be as beneficial as it sounds should be mega. Looks like the hard miles have been virtually done, just a little good fortune needed. |
Posted at 23/2/2024 07:22 by nobbygnome Pharma/biotech don’t take risks. The chances are they will wait for all the pre clinical work to be completed before they even contemplate a deal. Just imagine the poor guy who advocates signing the deal….and then it fails in a tox study. He will have serious egg on his face and his career will be blighted.N4P is desperate for cash and there really is no rush for Pharma to do a deal. Just wait for the N4P price to slump as another fund raise comes along… |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
